Previous 10 | Next 10 |
Koninklijke KPN NV (KKPNF) is expected to report for Q4 2023 ECA Marcellus Trust I Unit (ECTM) is expected to report for Q4 2023 San Juan Basin Royalty Trust (SJT) is expected to report for Q4 2023 Avenir Wellness Solutions Inc (AVRW) is expected to report for Q4 2023 Carmell Corp...
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy PR Newswire -- New weight loss drugs like Ozempic, Wegovy and Zepbound may make oral birth co...
Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
Kajima Corporation ADR (KAJMY) is expected to report for quarter end 2023-12-31 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 BrewBilt MFG Inc (BBRW) is expected to report for Q4 2023 Correlate Energy Corp. (CIPI) is expected to report for Q4 2023 Hyzon Motors Inc. (...
ESSA Pharma Inc. (EPIX) is expected to report $-0.17 for Q1 2024 QuidelOrtho Corp Com (QDEL) is expected to report $2.01 for Q4 2023 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 Portsmouth Square, Inc. (PRSI) is expected to report for Q2 2024 Similarweb Ltd. (SMWB) ...
2024-02-01 08:48:44 ET More on Evofem Biosciences Aditxt to acquire women’s health company Evofem Biosciences Seeking Alpha’s Quant Rating on Evofem Biosciences Historical earnings data for Evofem Biosciences Financial information for Evofem Bio...
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023 PR Newswire Evofem Delivers Third Consecutive Year of Phexxi Net Sales Growth Total Operating Expense Reduced More Than 60% from 2022 Levels SAN DIEGO ...
Aditxt (NASDAQ: ADTX) , a company dedicated to discovering, developing and deploying promising health innovations, has announced its acquisition of a portfolio of electroencephalography “EEG” brain monitoring technologies and devices formerly owned by Brain Scientific, Inc. The prod...
2024-01-30 08:39:35 ET More on Aditx Therapeutics Aditxt announces $6M private placement to fund its working capital Aditxt to acquire women’s health company Evofem Biosciences Seeking Alpha’s Quant Rating on Aditx Therapeutics Historical earnin...
News, Short Squeeze, Breakout and More Instantly...
ADiTx Therapeutics Inc. Company Name:
ADTX Stock Symbol:
NASDAQ Market:
ADiTx Therapeutics Inc. Website:
SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- Women’s health innovator Evofem Biosciences, Inc. (“Evofem” or “the Company”) (OTCQB: EVFM) today announced that Saundra Pelletier, Chief Executive Officer and Amy Raskopf, Chief Business Development Officer...
Appili, with a commercial-stage pipeline, has raised CAD $100M towards developing therapeutics for the global infectious disease and biodefense markets. Subject to the renewal of certain legislation, two programs are potentially eligible for FDA Priority Review Vouchers Aditxt, Inc. (...
Evofem Biosciences Inc. (OTCQB: EVFM) , a company commercializing innovative products to address unmet needs in women's sexual and reproductive health, has signed a license and supply agreement for the Middle East rights to Phexxi(R), Evofem's FDA-approved, hormone-free contra...